A5079473583- Ovarian function and disorders
- Ovarian cancer diagnosis and treatment
- Reproductive Biology and Fertility
- Coenzyme Q10 studies and effects
- Folate and B Vitamins Research
- Esophageal Cancer Research and Treatment
- Genetic Associations and Epidemiology
- Renal Diseases and Glomerulopathies
- Ferroptosis and cancer prognosis
- Cancer-related gene regulation
- Antioxidant Activity and Oxidative Stress
- Macrophage Migration Inhibitory Factor
- Helicobacter pylori-related gastroenterology studies
- Pancreatic and Hepatic Oncology Research
Dalian Medical University
2024-2025
First Affiliated Hospital of Dalian Medical University
2024-2025
China Medical University
2021-2022
Sheng Jing Hospital
2021
Canagliflozin (CANA), a kind of sodium-glucose cotransporter-2 (SGLT-2) inhibition, study in which the role CANA monotherapy polycystic ovary syndrome (PCOS) has been investigated, and it could become novel option PCOS treatment. Nevertheless, trials focused on SGLT-2 combination therapy's efficacy, safety patients are limited. This randomized controlled trial compared efficacy metformin (MET) therapy MET endocrine metabolic profiles overweight obese women with (PCOS).Fifty-one or...
ABSTRACT Background Altered glucose metabolism is a critical characteristic from the beginning stage of esophageal squamous cell carcinoma (ESCC), and phenomenon presented as pink‐color sign under endoscopy after iodine staining. Therefore, calculating metabolic score based on gene sets may bring some novel insights, enabling prediction prognosis identification treatment choices for ESCC. Methods A total 8, 99, 140 individuals The Gene Expression Omnibus database, Cancer Genome Atlas...
Esophageal squamous cell carcinoma (ESCC) represents a frequent cancer with poor prognosis. Altered glucose metabolism contributes factor to ESCC progression. In our previous study, signal sequence receptor subunit delta (SSR4) was included in an prognostic model; however, the mechanisms underlying SSR4 implication remain ambiguous. Accordingly, we aim determine interconnection between expression and clinical characteristics of ESCC. This differential significance performed using bulk...
Introduction Polycystic ovary syndrome (PCOS) is a heterogeneous reproductive endocrine disorder. Several ongoing trials test sodium-glucose cotransporter-2 (SGLT-2) inhibitors for women with PCOS. However, their effectiveness has not been fully elucidated owing to the lack of high-confidence evidence. Our group agrees statement that SGLT-2 inhibition could treat PCOS as it supported by reports demonstrating benefits on metabolic status and weight control. Moreover, functions chronic...
Background Polycystic ovary syndrome (PCOS) is defined by oligo/anovulation, hyperandrogenism, and polycystic ovaries with uncertain pathogenesis. The proteome represents a substantial source of therapeutic targets, their coding genes may elucidate the mechanisms underlying PCOS. However, reports on profiles human plasma protein-coding PCOS are limited. Here, we aimed to investigate novel biomarkers or drug targets for integrating genetics proteome. Methods Our study acquired protein...